ECMO for severe ARDS: systematic review and individual patient data meta-analysis

Area of Science:

• Critical Care Medicine
• Respiratory Medicine
• Cardiopulmonary Support

Background:

• Severe acute respiratory distress syndrome (ARDS) presents a significant challenge in critical care.
• Conventional management strategies for ARDS have limitations in improving outcomes for the most severe cases.

Purpose of the Study:

• To evaluate the efficacy of venovenous extracorporeal membrane oxygenation (ECMO) versus conventional management in patients with severe ARDS.
• To determine the impact of ECMO on 90-day mortality in this patient population.

Main Methods:

• A systematic review and individual patient data meta-analysis of randomized controlled trials (RCTs) were performed.
• Two RCTs (CESAR and EOLIA) involving 429 patients with severe ARDS were included.
• The primary outcome assessed was 90-day mortality, analyzed using an intent-to-treat approach.

Main Results:

• ECMO significantly reduced 90-day mortality, with 36% mortality in the ECMO group versus 48% in the control group (RR, 0.75; P=0.013).
• Treatment failure, defined as death or crossover to ECMO, was also significantly lower in the ECMO group (RR, 0.65).
• Patients receiving ECMO experienced more days alive and free from organ failure (respiratory, cardiovascular, renal, neurological).

Conclusions:

• Venovenous ECMO is associated with significantly lower 90-day mortality in patients with severe ARDS.
• ECMO improves survival and reduces organ failure burden in critically ill ARDS patients.
• The benefit of ECMO was particularly pronounced in patients with two or fewer failing organs at randomization.